Literature DB >> 20970876

Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.

Umut Dişel1, Serdar Oztuzcu, Ali Ayberk Beşen, Cemile Karadeniz, Fatih Köse, Ahmet Taner Sümbül, Ahmet Sezer, Gül Nihal Nursal, Hüseyin Abalı, Ozgür Ozyılkan.   

Abstract

Advanced thymic carcinoma (TC) is a very aggressive disease. To date there are no established treatment options for the refractory and recurrent disease and only a few prospective trials have been conducted in patients with TC. Here we present a case of a relapsed TC patient, who, by using combination chemotherapy, showed a positive response to sorafenib with C-KIT exon 11 mutation.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 20970876     DOI： 10.1016/j.lungcan.2010.09.011

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  8 in total

1.  Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

Authors:  Thomas Neuhaus; Joachim Luyken
Journal:  Target Oncol       Date:  2012-10-23       Impact factor: 4.493

2.  c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report.

Authors:  Fumihiko Hirai; Makoto Edagawa; Shinichiro Shimamatsu; Ryo Toyozawa; Gouji Toyokawa; Kaname Nosaki; Masafumi Yamaguchi; Takashi Seto; Mitsuhiro Twakenoyama; Yukito Ichinose
Journal:  Mol Clin Oncol       Date:  2016-01-28

3.  Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.

Authors:  Tracey L Evans
Journal:  Onco Targets Ther       Date:  2012-09-07       Impact factor: 4.147

4.  Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Authors:  Chiara Catania; Fabio Conforti; Gianluca Spitaleri; Massimo Barberis; Lorenzo Preda; Cristina Noberasco; Chiara Lazzari; Francesca Toffalorio; Filippo de Marinis; Michela Manzotti; Tommaso Martino De Pas
Journal:  Onco Targets Ther       Date:  2014-05-08       Impact factor: 4.147

Review 5.  Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.

Authors:  Maryam Abbaspour Babaei; Behnam Kamalidehghan; Mohammad Saleem; Hasniza Zaman Huri; Fatemeh Ahmadipour
Journal:  Drug Des Devel Ther       Date:  2016-08-01       Impact factor: 4.162

6.  Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial.

Authors:  Zhengbo Song; Guangyuan Lou; Yina Wang; Zhiping Yang; Wenxian Wang; Yongling Ji; Shiqing Chen; Chunwei Xu; Xiao Hu; Yiping Zhang
Journal:  BMC Med       Date:  2022-05-10       Impact factor: 8.775

7.  Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.

Authors:  Adam Szpechcinski; Malgorzata Szolkowska; Sebastian Winiarski; Urszula Lechowicz; Piotr Wisniewski; Magdalena Knetki-Wroblewska
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

Review 8.  [Research status of molecular targeted therapy in thymic epithelial tumors].

Authors:  Lizhu Chen; Kailiang Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.